ONTOLOGY REPORT - ANNOTATIONS
| Term: | organic salt |
|
| Accession: | CHEBI:24868
|
browse the term
|
| Synonyms: | related_synonym: | organic salts; organisches Salz |
|
|
(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride
|
| G |
Drd1 |
dopamine receptor D1 |
|
multiple interactions |
ISO |
17 |
16,655,926 |
16,658,161 |
RGD:6480464 |
CTD |
| G |
Drd1 |
dopamine receptor D1 |
|
affects localization |
ISO |
17 |
16,655,926 |
16,658,161 |
RGD:6480464 |
CTD |
1,1-dimethyl-4-phenylpiperazinium iodide
|
| G |
Chrna2 |
cholinergic receptor, nicotinic, alpha 2 (neuronal) |
|
multiple interactions |
ISO |
15 |
45,570,809 |
45,587,091 |
RGD:6480464 |
CTD |
| G |
Chrna3 |
cholinergic receptor, nicotinic, alpha 3 (neuronal) |
|
multiple interactions |
ISO |
8 |
58,570,223 |
58,583,594 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna7 |
cholinergic receptor, nicotinic, alpha 7 (neuronal) |
|
multiple interactions |
ISO |
1 |
117,587,580 |
117,716,267 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb4 |
cholinergic receptor, nicotinic, beta 4 (neuronal) |
|
multiple interactions |
ISO |
8 |
58,586,961 |
58,605,545 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases activity |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Aco2 |
aconitase 2, mitochondrial |
|
multiple interactions |
ISO |
7 |
120,223,788 |
120,266,944 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate
|
| G |
Calca |
calcitonin-related polypeptide alpha |
|
decreases expression |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled |
|
affects binding |
EXP |
8 |
86,700,088 |
86,701,248 |
RGD:6480464 |
CTD |
4-fluoro-N-\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\}benzamide hydrochloride
|
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
5-methylphenazinium methyl sulfate
|
| G |
G6pd |
glucose-6-phosphate dehydrogenase |
|
increases activity |
ISO |
X |
160,186,450 |
160,192,316 |
RGD:6480464 |
CTD |
| G |
Pgd |
phosphogluconate dehydrogenase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
acridine orange
|
| G |
Bax |
Bcl2-associated X protein |
|
increases response to substance |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
multiple interactions |
ISO |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
ambenonium chloride
|
| G |
App |
amyloid beta (A4) precursor protein |
|
affects cleavage |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
ammonium acetate
|
| G |
Ada |
adenosine deaminase |
|
increases activity |
EXP |
3 |
154,636,530 |
154,660,637 |
RGD:6480464 |
CTD |
| G |
Ampd3 |
adenosine monophosphate deaminase 3 |
|
increases activity |
EXP |
1 |
168,519,462 |
168,568,291 |
RGD:6480464 |
CTD |
| G |
Asl |
argininosuccinate lyase |
|
increases activity |
EXP |
12 |
27,702,882 |
27,720,230 |
RGD:6480464 |
CTD |
| G |
Ass1 |
argininosuccinate synthase 1 |
|
increases activity |
EXP |
3 |
10,578,717 |
10,622,332 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Grin2a |
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
|
multiple interactions |
EXP |
10 |
5,588,229 |
6,004,780 |
RGD:6480464 |
CTD |
| G |
Grin2a |
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
|
decreases expression |
EXP |
10 |
5,588,229 |
6,004,780 |
RGD:6480464 |
CTD |
| G |
Grin2b |
glutamate receptor, ionotropic, N-methyl D-aspartate 2B |
|
decreases expression |
EXP |
4 |
172,721,895 |
173,183,187 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
multiple interactions |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
increases activity |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases expression |
EXP |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
decreases activity |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Xdh |
xanthine dehydrogenase |
|
affects activity |
EXP |
6 |
21,417,685 |
21,590,015 |
RGD:6480464 |
CTD |
| G |
Xdh |
xanthine dehydrogenase |
|
multiple interactions |
EXP |
6 |
21,417,685 |
21,590,015 |
RGD:6480464 |
CTD |
chloramine T
|
| G |
Cd86 |
CD86 molecule |
|
increases expression |
ISO |
11 |
66,215,233 |
66,238,882 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Msra |
methionine sulfoxide reductase A |
|
decreases response to substance |
ISO |
15 |
43,509,775 |
43,756,283 |
RGD:6480464 |
CTD |
| G |
Msra |
methionine sulfoxide reductase A |
|
multiple interactions |
ISO |
15 |
43,509,775 |
43,756,283 |
RGD:6480464 |
CTD |
| G |
Nrgn |
neurogranin |
|
multiple interactions |
EXP |
8 |
38,790,596 |
38,799,077 |
RGD:6480464 |
CTD |
| G |
Nrgn |
neurogranin |
|
affects phosphorylation |
EXP |
8 |
38,790,596 |
38,799,077 |
RGD:6480464 |
CTD |
| G |
Selp |
selectin P |
|
decreases expression |
ISO |
13 |
79,886,614 |
79,922,180 |
RGD:6480464 |
CTD |
cinacalcet hydrochloride
|
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases activity |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases activity |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
decreases expression |
ISO |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
decreases expression |
ISO |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
| G |
Pth |
parathyroid hormone |
|
decreases secretion |
ISO |
1 |
171,240,596 |
171,243,528 |
RGD:6480464 |
CTD |
colesevelam hydrochloride
|
| G |
Crp |
C-reactive protein, pentraxin-related |
|
decreases expression |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
increases expression |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
increases expression |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
dimenhydrinate
|
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
disodium cromoglycate
|
| G |
Adora3 |
adenosine A3 receptor |
|
decreases activity |
EXP |
2 |
201,157,782 |
201,161,425 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Ctsd |
cathepsin D |
|
multiple interactions |
ISO |
1 |
202,619,669 |
202,631,545 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
multiple interactions |
EXP |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
increases expression |
EXP |
19 |
15,246,036 |
15,275,061 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Tac1 |
tachykinin, precursor 1 |
|
multiple interactions |
EXP |
4 |
32,649,666 |
32,657,632 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
donepezil hydrochloride
|
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
affects activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
increases abundance |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
decreases response to substance |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases activity |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
EXP |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Nppb |
natriuretic peptide B |
|
decreases expression |
ISO |
5 |
165,062,348 |
165,063,650 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
multiple interactions |
EXP |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
dorzolamide hydrochloride
|
| G |
Ca2 |
carbonic anhydrase 2 |
|
multiple interactions |
ISO |
2 |
88,077,095 |
88,092,223 |
RGD:6480464 |
CTD |
| G |
Car3 |
carbonic anhydrase 3 |
|
multiple interactions |
ISO |
2 |
88,106,727 |
88,114,686 |
RGD:6480464 |
CTD |
erythromycin estolate
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases expression |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Acadm |
acyl-CoA dehydrogenase, C-4 to C-12 straight chain |
|
decreases expression |
EXP |
2 |
251,866,645 |
251,890,729 |
RGD:6480464 |
CTD |
| G |
Acly |
ATP citrate lyase |
|
decreases expression |
EXP |
10 |
89,420,934 |
89,471,398 |
RGD:6480464 |
CTD |
| G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
|
decreases expression |
EXP |
16 |
49,036,892 |
49,081,416 |
RGD:6480464 |
CTD |
| G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
|
decreases expression |
EXP |
10 |
47,400,518 |
47,421,064 |
RGD:6480464 |
CTD |
| G |
Apex1 |
APEX nuclease (multifunctional DNA repair enzyme) 1 |
|
decreases expression |
EXP |
15 |
26,904,124 |
26,906,224 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
decreases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
EXP |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
Calu |
calumenin |
|
increases expression |
EXP |
4 |
56,228,617 |
56,256,118 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ceacam1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
decreases expression |
EXP |
1 |
80,742,540 |
80,758,943 |
RGD:6480464 |
CTD |
| G |
Ctsl1 |
cathepsin L1 |
|
increases expression |
EXP |
17 |
6,288,013 |
6,294,174 |
RGD:6480464 |
CTD |
| G |
Cyb5r3 |
cytochrome b5 reductase 3 |
|
decreases expression |
EXP |
7 |
121,187,821 |
121,205,382 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases expression |
EXP |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
increases expression |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
increases expression |
EXP |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
EXP |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fads1 |
fatty acid desaturase 1 |
|
decreases expression |
EXP |
1 |
212,670,792 |
212,685,718 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Fga |
fibrinogen alpha chain |
|
increases expression |
EXP |
2 |
174,737,640 |
174,753,598 |
RGD:6480464 |
CTD |
| G |
Fgb |
fibrinogen beta chain |
|
increases expression |
EXP |
2 |
174,768,193 |
174,775,102 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
decreases expression |
EXP |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
|
increases expression |
EXP |
4 |
96,649,941 |
96,652,243 |
RGD:6480464 |
CTD |
| G |
Gck |
glucokinase |
|
decreases expression |
EXP |
14 |
86,572,518 |
86,587,723 |
RGD:6480464 |
CTD |
| G |
Gpx1 |
glutathione peroxidase 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Gstm3 |
glutathione S-transferase mu 3 |
|
decreases expression |
EXP |
2 |
203,532,363 |
203,537,135 |
RGD:6480464 |
CTD |
| G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
|
decreases expression |
EXP |
4 |
80,850,300 |
80,948,361 |
RGD:6480464 |
CTD |
| G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
|
increases expression |
EXP |
14 |
87,950,222 |
87,955,289 |
RGD:6480464 |
CTD |
| G |
Krt18 |
keratin 18 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Lbp |
lipopolysaccharide binding protein |
|
increases expression |
EXP |
3 |
149,016,605 |
149,043,530 |
RGD:6480464 |
CTD |
| G |
Lgals3 |
lectin, galactoside-binding, soluble, 3 |
|
increases expression |
EXP |
15 |
23,327,071 |
23,339,006 |
RGD:6480464 |
CTD |
| G |
Lipc |
lipase, hepatic |
|
decreases expression |
EXP |
8 |
75,323,442 |
75,450,353 |
RGD:6480464 |
CTD |
| G |
Lpl |
lipoprotein lipase |
|
increases expression |
EXP |
16 |
22,533,105 |
22,556,905 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases expression |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta |
|
decreases expression |
EXP |
1 |
83,865,440 |
83,873,010 |
RGD:6480464 |
CTD |
| G |
Otc |
ornithine carbamoyltransferase |
|
decreases expression |
EXP |
X |
24,609,141 |
24,685,341 |
RGD:6480464 |
CTD |
| G |
Pklr |
pyruvate kinase, liver and RBC |
|
decreases expression |
EXP |
2 |
181,214,853 |
181,223,505 |
RGD:6480464 |
CTD |
| G |
Pygl |
phosphorylase, glycogen, liver |
|
decreases expression |
EXP |
6 |
92,298,339 |
92,341,347 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
increases expression |
EXP |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
increases expression |
EXP |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
Slco1b3 |
solute carrier organic anion transporter family, member 1b3 |
|
decreases expression |
EXP |
4 |
179,045,586 |
179,118,680 |
RGD:6480464 |
CTD |
| G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
|
decreases expression |
EXP |
10 |
46,461,684 |
46,483,646 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
increases expression |
EXP |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Thrsp |
thyroid hormone responsive |
|
decreases expression |
EXP |
1 |
154,647,339 |
154,651,663 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
EXP |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
increases expression |
EXP |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
decreases expression |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Ttr |
transthyretin |
|
decreases expression |
EXP |
18 |
12,406,571 |
12,413,680 |
RGD:6480464 |
CTD |
| G |
Txnrd1 |
thioredoxin reductase 1 |
|
decreases expression |
EXP |
7 |
23,055,544 |
23,093,815 |
RGD:6480464 |
CTD |
erythrosine sodium
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
increases activity |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
increases expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
increases expression |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases activity |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trh |
thyrotropin releasing hormone |
|
multiple interactions |
EXP |
4 |
126,425,212 |
126,427,670 |
RGD:6480464 |
CTD |
| G |
Tshb |
thyroid stimulating hormone, beta |
|
multiple interactions |
EXP |
2 |
197,908,308 |
197,913,186 |
RGD:6480464 |
CTD |
| G |
Ugt1a6 |
UDP glucuronosyltransferase 1 family, polypeptide A6 |
|
decreases activity |
ISO |
9 |
87,037,154 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
decreases activity |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
metamizole sodium
|
| G |
Crh |
corticotropin releasing hormone |
|
multiple interactions |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
EXP |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
methylene blue
|
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
G6pd |
glucose-6-phosphate dehydrogenase |
|
increases activity |
ISO |
X |
160,186,450 |
160,192,316 |
RGD:6480464 |
CTD |
| G |
Gnrh1 |
gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) |
|
multiple interactions |
EXP |
15 |
47,303,309 |
47,307,517 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
multiple interactions |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
decreases expression |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
increases expression |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Pgd |
phosphogluconate dehydrogenase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases activity |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
NAN 190 hydrobromide
|
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
nitro blue tetrazolium dichloride
|
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
affects response to substance |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
pentolinium tartrate
|
| G |
Ins2 |
insulin 2 |
|
multiple interactions |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
phosphorylcholine chloride
|
| G |
Fasn |
fatty acid synthase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
increases expression |
ISO |
8 |
4,333,773 |
4,354,284 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
multiple interactions |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
quinapril hydrochloride
|
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
ISO |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Adm |
adrenomedullin |
|
decreases expression |
EXP |
1 |
168,380,255 |
168,382,426 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
decreases activity |
EXP |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
|
decreases expression |
EXP |
14 |
17,265,986 |
17,268,183 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
decreases expression |
ISO |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
decreases activity |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F5 |
coagulation factor V (proaccelerin, labile factor) |
|
decreases activity |
ISO |
13 |
79,934,956 |
79,997,285 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
affects expression |
EXP |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases expression |
EXP |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases secretion |
EXP |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Pthlh |
parathyroid hormone-like hormone |
|
multiple interactions |
EXP |
4 |
184,887,702 |
184,898,841 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
multiple interactions |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Ren |
renin |
|
increases expression |
EXP |
13 |
46,262,936 |
46,275,213 |
RGD:6480464 |
CTD |
| G |
Slc15a1 |
solute carrier family 15 (oligopeptide transporter), member 1 |
|
multiple interactions |
ISO |
15 |
106,549,586 |
106,592,594 |
RGD:6480464 |
CTD |
| G |
Slc15a2 |
solute carrier family 15 (H+/peptide transporter), member 2 |
|
multiple interactions |
ISO |
11 |
65,819,551 |
65,849,924 |
RGD:6480464 |
CTD |
| G |
Slc15a2 |
solute carrier family 15 (H+/peptide transporter), member 2 |
|
multiple interactions |
EXP |
11 |
65,819,551 |
65,849,924 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
rabeprazole sodium
|
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
multiple interactions |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases expression |
ISO |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Slc18a2 |
solute carrier family 18 (vesicular monoamine), member 2 |
|
multiple interactions |
EXP |
1 |
265,789,917 |
265,824,551 |
RGD:6480464 |
CTD |
rose bengal
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Gsta3 |
glutathione S-transferase alpha 3 |
|
decreases response to substance |
EXP |
9 |
20,005,570 |
20,032,031 |
RGD:6480464 |
CTD |
| G |
Ugt1a6 |
UDP glucuronosyltransferase 1 family, polypeptide A6 |
|
decreases activity |
ISO |
9 |
87,037,154 |
87,098,362 |
RGD:6480464 |
CTD |
sodium acetate trihydrate
|
| G |
Apob |
apolipoprotein B |
|
multiple interactions |
ISO |
6 |
31,508,060 |
31,548,083 |
RGD:6480464 |
CTD |
sodium aurothiomalate
|
| G |
Cd28 |
Cd28 molecule |
|
multiple interactions |
ISO |
9 |
59,342,273 |
59,367,743 |
RGD:6480464 |
CTD |
| G |
Cd28 |
Cd28 molecule |
|
affects response to substance |
ISO |
9 |
59,342,273 |
59,367,743 |
RGD:6480464 |
CTD |
| G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
|
multiple interactions |
ISO |
1 |
249,122,845 |
249,158,369 |
RGD:6480464 |
CTD |
| G |
Fbl |
fibrillarin |
|
affects localization |
ISO |
1 |
83,271,967 |
83,281,069 |
RGD:6480464 |
CTD |
| G |
Fbl |
fibrillarin |
|
multiple interactions |
ISO |
1 |
83,271,967 |
83,281,069 |
RGD:6480464 |
CTD |
| G |
Fbl |
fibrillarin |
|
decreases activity |
ISO |
1 |
83,271,967 |
83,281,069 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
affects response to substance |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
multiple interactions |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
affects response to substance |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
affects response to substance |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Txnrd1 |
thioredoxin reductase 1 |
|
multiple interactions |
ISO |
7 |
23,055,544 |
23,093,815 |
RGD:6480464 |
CTD |
| G |
Txnrd1 |
thioredoxin reductase 1 |
|
decreases activity |
EXP |
7 |
23,055,544 |
23,093,815 |
RGD:6480464 |
CTD |
| G |
Txnrd2 |
thioredoxin reductase 2 |
|
decreases activity |
EXP |
11 |
84,513,361 |
84,561,673 |
RGD:6480464 |
CTD |
sodium cholate
|
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
sodium hydrogencarbonate
|
| G |
Fn1 |
fibronectin 1 |
|
multiple interactions |
EXP |
9 |
70,702,181 |
70,771,155 |
RGD:6480464 |
CTD |
| G |
Slc39a8 |
solute carrier family 39 (zinc transporter), member 8 |
|
multiple interactions |
EXP |
2 |
233,340,397 |
233,403,461 |
RGD:6480464 |
CTD |
| G |
Slc4a4 |
solute carrier family 4, sodium bicarbonate cotransporter, member 4 |
|
increases transport |
ISO |
14 |
20,381,545 |
20,739,216 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Vim |
vimentin |
|
multiple interactions |
EXP |
17 |
87,847,280 |
87,855,763 |
RGD:6480464 |
CTD |
sodium thiocyanate
|
| G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
|
multiple interactions |
ISO |
16 |
19,046,200 |
19,056,281 |
RGD:6480464 |
CTD |
tartrazine
|
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases activity |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
multiple interactions |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
| G |
Tff1 |
trefoil factor 1 |
|
increases expression |
ISO |
20 |
9,526,674 |
9,530,534 |
RGD:6480464 |
CTD |
vanoxerine dihydrochloride
|
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
multiple interactions |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases degradation |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases degradation |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases degradation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
multiple interactions |
ISO |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
affects expression |
EXP |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Slc18a2 |
solute carrier family 18 (vesicular monoamine), member 2 |
|
affects binding |
ISO |
1 |
265,789,917 |
265,824,551 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
affects binding |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
decreases response to substance |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
affects response to substance |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
EXP |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
multiple interactions |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
| G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
decreases activity |
ISO |
1 |
30,516,568 |
30,557,540 |
RGD:6480464 |
CTD |
vecuronium bromide
|
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
multiple interactions |
ISO |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
multiple interactions |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
multiple interactions |
ISO |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
|
multiple interactions |
ISO |
3 |
76,301,988 |
76,309,729 |
RGD:6480464 |
CTD |
| G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
|
multiple interactions |
ISO |
3 |
98,326,809 |
98,378,531 |
RGD:6480464 |
CTD |
| G |
Chrna3 |
cholinergic receptor, nicotinic, alpha 3 (neuronal) |
|
multiple interactions |
ISO |
8 |
58,570,223 |
58,583,594 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna7 |
cholinergic receptor, nicotinic, alpha 7 (neuronal) |
|
multiple interactions |
ISO |
1 |
117,587,580 |
117,716,267 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb4 |
cholinergic receptor, nicotinic, beta 4 (neuronal) |
|
multiple interactions |
ISO |
8 |
58,586,961 |
58,605,545 |
RGD:6480464 |
CTD |
| G |
Hexb |
hexosaminidase B |
|
increases secretion |
ISO |
2 |
27,649,188 |
27,672,231 |
RGD:6480464 |
CTD |
Term paths to the root
|